Nintedanib combined with pirfenidone: is the efficacy additive?

With the gradual enrichment of treatment methods for idiopathic pulmonary fibrosis (IPF), the two main anti-fibrosis drugs currently widely used internationally are Nintedanib (Nintedanib) and pirfenidone. They slow down the progression of lung tissue fibrosis through different mechanisms. Among them, nintedanib mainly targets multiple tyrosine kinase receptors and inhibits fibroblast activation and proliferation; while pirfenidone has dual anti-inflammatory and antioxidant effects and can regulate key inflammatory signaling pathways such as TGF-β. This difference in mechanism prompts clinicians to continuously explore whether the combined use of the two can produce synergistic or additive effects.

Theoretically, the mechanisms of action of the two drugs are complementary, and their combined use may bring about a more comprehensive anti-fibrotic effect. However, there is currently no unified conclusion as to whether there is actual "efficacy stacking". Some small-scale clinical studies abroad have tried to combine nintedanib and pirfenidone. In some patients, it was observed that the decline of lung function was slightly slowed down and the improvement of inflammatory indicators was enhanced. However, at the same time, some studies have pointed out that combination therapy significantly increases the incidence of adverse reactions, especially gastrointestinal discomfort, loss of appetite, skin photosensitivity, and abnormal liver function, which reduces patient tolerance and compliance.

More importantly, the two drugs are currently not recommended as routine combination treatments in the instructions of many countries and regions around the world, and can only be "individualized attempts" under special circumstances. This also shows that their clinical promotion still needs to be supported by more large-scale, long-term follow-up randomized controlled trial data. Therefore, for most IPF patients, it is still a more prudent strategy to give priority to single-drug regimens and seek a balance between drug efficacy and side effects.

Reference materials:https://en.wikipedia.org/wiki/Nintedanib